Pharmacy World and Science

, Volume 27, Issue 1, pp 41–46 | Cite as

Initial benzodiazepine use and improved health-related quality of life

  • Rolf van HultenEmail author
  • Bart Teeuw
  • Albert Bakker
  • Hubert G. Leufkens



The health-related quality of life (HRQOL) of initial benzodiazepine users was measured over time. Furthermore, benzodiazepineusage characteristics as determinants of change in mental and physical health status of the benzodiazepine users were examined.


In the only pharmacy of a Dutch community of 13500 and during four months from November 1994, all patients with a benzodiazepine prescription and no history of benzodiazepine use over a period of 12 months before inclusion, were invited to participate. A total of 106 initial benzodiazepine users were matched for age and gender. In a six-month follow-up study, HRQOL was measured with the RAND-36. Consequently, in a nested case control design, determinants of change in mental and physical functioning over the six-month period were analysed using the Mental Component Summary and the Physical Component Summary.


At baseline, initial benzodiazepine users showed a lower HRQOL as compared to reference subjects. After six-month follow-up, enzodiazepine users presented an absolute increase in HRQOL, while the reference subjects maintained a stable HRQOL. Diazepam and the male gender were associated with an increase in physical functioning over time. Younger age, a lower daily dose (DDD < 0.75) and a period of use between 16 and 60 days were associated with better mental functioning over time.


This study is one of the first to associate improvement in HRQOL over time of starting benzodiazepine users with specific usage characteristics, such as limited duration of use and a low dosage.


Benzodiazepines Health status Quality of life Rand-36 Summary measures The Netherlands 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Hollister, LE. 1983The pre-benzodiazepine eraPsychoactive Drugs15129 –13Google Scholar
  2. Hollister, L, Molzenbecker, F, Degan, R. 1961Withdrawal reactions from chlordiazepoxide (Librium)Psychopharmacologia2638CrossRefPubMedGoogle Scholar
  3. Petursson, H, Lader, MH. 1981Benzodiazepine dependenceBr J Addict7613345PubMedGoogle Scholar
  4. Lader, MH. 1983Dependence on benzodiazepinesJ Clin Psychiatry441217Google Scholar
  5. Owen, RT, Tyrer, P. 1983Benzodiazepine dependence: a review of evidenceDrugs2538598PubMedGoogle Scholar
  6. Mellinger, GD, Balter, MB, Uhlenhuth, EH. 1984Anti-anxiety agents: duration of use and characteristics of users in the U.S.ACurr Med Res Opin84(Suppl)Google Scholar
  7. Olfson, M, Pincus, HA. 1994Use of benzodiazepines in the communityArch Intern Med154123540CrossRefPubMedGoogle Scholar
  8. Dunbar, GC, Perera, MH, Jenner, FA. 1989Patterns of benzodiazepine use in Great Britain as measured by a General Population SurveyBr J Psychiatry15583641PubMedGoogle Scholar
  9. Tyrer, P, Owen, R. 1984Anxiety in primary care: is short term drug treatment appropriate?J Psychiatr Res18738CrossRefPubMedGoogle Scholar
  10. Lader, MH, Petursson, H. 1983Rational use of anxiolytic/sedative drugsDrugs2551428PubMedGoogle Scholar
  11. Committee on the review of medicines1980Systematic review of the benzodiazepinesBMJ14191721Google Scholar
  12. Greenblatt, DJ, Shader, RI. 1974Benzodiazepines in clinical practiceRaven PressNew YorkGoogle Scholar
  13. Rickles, K, Downing, RW. 1976Drug and placebo treated neurotic outpatientsArch Gen Psychiatry1636972Google Scholar
  14. Dasberg, H, Praag, HM. 1974The therapeutic effect of short term oral diazepam treatment on acute clinical anxiety in a crisis centreActa Psychiatr Scand5032640PubMedGoogle Scholar
  15. Shapiro, AK, Sruening, EL, Shapiro, E, Milcarek, BI. 1984Diazepam: how much better than placebo?J Psychiatric Res185173Google Scholar
  16. Catalan, J, Gath, D. 1985Benzodiazepines in general practice: time for a decisionBMJ29013746PubMedGoogle Scholar
  17. Catalan, J, Gath, DH, Bond, A, Edmonds, G, Martin, P, Ennis, J. 1988General practice patients on long term psychotropic drugsBr J Psychiatry152399PubMedGoogle Scholar
  18. Mellinger, GD, Balter, MB, Uhlenhuth, EH. 1984Prevalence and correlates of the long-term use of anxiolyticsJAMA2513759CrossRefPubMedGoogle Scholar
  19. Simpson, RJ, Power, KG, Wallace, LA, Butcher, MH, Swanson, V, Simpson, EC. 1990Controlled comparison of the characteristics of long-term benzodiazepine users in general practiceBr J Gen Pract40226PubMedGoogle Scholar
  20. Rodrigo, EK, King, MB, Williams, P. 1988Health of long term benzodiazepine usersBMJ2966036PubMedGoogle Scholar
  21. Mant, A, Mattick, RP, Burgh, S, Donnelly, N, Hall, W. 1995Benzodiazepine prescribing in general practice: dispelling some mythsFam Pract123743PubMedGoogle Scholar
  22. Romach, M, Busto, U, Somer, G, Kaplan, HL, Sellers, E. 1995Clinical aspects of chronic use of alprazolam and lorazepamAm J Psychiatry15211617PubMedGoogle Scholar
  23. Hulten, R. 2000Characteristics of current benzodiazepine users as indicators of differences in physical and mental healthPharm World Sci2296101CrossRefPubMedGoogle Scholar
  24. Marino, S. 1993Ill-health and social predictors of psychotropic drug prescription in general practiceInt J Soc Psychiatry3916776PubMedGoogle Scholar
  25. Douglas Ried, L, Johnson, RE, Gettman, DA. 1998Benzodiazepine exposure and functional status in older peopleJ Am Geriatr Soc46716PubMedGoogle Scholar
  26. Ashton, H. 1994Guidelines for the rational use of benzodiazepines. What and what to useDrugs482440Google Scholar
  27. Zee, KI, Sanderman, R. 1993Het meten van de algemene gezondheidstoestand met de RAND-36. Een handleiding. [Measuring general health status with the RAND-36. Users manual.] GroningenNorthern Center of Health Care ResearchThe Netherlands[in Dutch]Google Scholar
  28. Ware, JE, Sherbourne, CD. 1992The MOS 36-Item Short-Form Health Survey (SF-36), I: Conceptual framework and item selectionMed Care3047383PubMedGoogle Scholar
  29. Hays, RD, Sherbourne, CD, Mazel, RM. 1993The RAND 36-Item Health Survey 1.0Health Econ221727PubMedGoogle Scholar
  30. Ware, JE, Koskinski, M, Keller, SD. 1994SF-36 physical and mental summary scales: a user’s manualThe Health InstituteBoston, MassachusettsGoogle Scholar
  31. Ware, JE, Kosinski, M, Bayliss, MS, McHorney, CA, Rogers, WH, Raczek, A. 1995Comparison of Methods for the Scoring and Statistical Analysis of SF-36 health profile and summary measures: Summary of results from the medical putcome studyMed Care33AS26479PubMedGoogle Scholar
  32. Morrin, L, Black, S, Reid, R. 2000Impact of duration in a cardiac rehabilitation program on coronary risk profile and health-related quality of life outcomesJ Cardiopulm Rehab2011521CrossRefGoogle Scholar
  33. Korf, M, Wagner, EH, Saunders, K. 1992A chronic disease score from automated pharmacy dataJ Clin Epidemiol45197203CrossRefPubMedGoogle Scholar
  34. Nazareth, ID, King, MD. 1989Prescribing of benzodiazepines by casualty officersJ R Soc Med822767PubMedGoogle Scholar
  35. Hulten, R, Bakker, AB, Lodder, AC, Teeuw, KB, Bakker, A, Leufkens, HG 2001Determinants of change in the intention to use benzodiazepinesPharm World Sci23705CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Rolf van Hulten
    • 1
    Email author
  • Bart Teeuw
    • 1
  • Albert Bakker
    • 1
  • Hubert G. Leufkens
    • 1
  1. 1.Department of Pharmacoepidemiology and PharmacotherapyUtrecht UniversityTB UtrechtThe Netherlands

Personalised recommendations